Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VentiRx Pharmaceuticals Inc.

www.ventirx.com

Latest From VentiRx Pharmaceuticals Inc.

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity

In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.

BioPharmaceutical Clinical Trials

Deals Of The Week Keeps Tabs As Tax Trimming Fuels Deal-Making

As more biopharmaceutical companies become profitable and global, tax strategy becomes an increasingly important aspect of deal-making and intellectual property management. Deals of the Week looks at recent tax winners, new tax tactics and potential deal targets that are attractive in part because of their high – or low – tax rates.

BioPharmaceutical Deals

Pharma-biotech collaborations: Eight themes from Biocom's Partnering Conference

Big pharma, small biotech and academic institutions are experimenting with new ways of working together, and San Diego's life science industry group Biocom invited deal makers to town on 26 and 27 February to share their ideas.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • VentiRx Pharmaceuticals Inc.
  • Senior Management
  • Robert Hershberg, MD, PhD, CEO
    Tom Swallow, VP, Fin.
    Gregory N Dietsch, PhD, VP, Research
    James Kyle Bryan, MD, CMO
  • Contact Info
  • VentiRx Pharmaceuticals Inc.
    Phone: (206) 689-2259
    1301 Second Ave.
    Ste. 2800
    Seattle, WA 98101
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register